Kim Smith-Whitley - Jun 1, 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Officer Title: EVP, Head of Research & Development
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Jun 1, 2022
Transactions value $
-$39,873
Form type
4
Date filed
6/3/2022, 05:06 PM
Previous filing
Mar 3, 2022
Next filing
Sep 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +6.04K 6.04K Jun 1, 2022 Direct F1
transaction GBT Common Stock Tax liability -$39.9K -1.66K -27.48% $24.02 4.38K Jun 1, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -6.04K -25% $0.00 18.1K Jun 1, 2022 Common Stock 6.04K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,040 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vested with respect to 25% of the underlying shares on June 1, 2022 and will vest in six equal semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Officer Title: EVP, Head of Research & Development